Lantheus Holdings $LNTH Dark Pool Buy Orders, Raised Forward Guidance

  • Post category:Dark Pool Stocks
  • Reading time:5 mins read
Get Email Alerts and Follow Us:

Lantheus Holdings $LNTH rose more than 10% on August 5, 2022, after the company raised forward guidance. In the weeks leading up to the Q2 earnings release and raised forward guidance, dark pool activity was detected in the stock of Lantheus Holdings.

Dark Pool Activity in $LNTH Stock

Guerilla Stock Trading detected dark pool activity in $LNTH. The price action following the dark pool prints suggests that it was buy orders coming off dark pools. The multi-million dollar orders indicate that it was a deep-pocketed institutional investor(s) wanting to hide their orders.

Lnth Dark Pool Activity

Make sure to review this lesson on dark pool trading so that you understand the chart above.

Lantheus Holdings, Inc. is involved in developing, manufacturing, selling, and distributing diagnostic medical imaging agents and products for diagnosing cardiovascular and other diseases. It serves hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies, and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.

Lantheus Reports Second Quarter 2022 Financial Results

On August 4, 2022, Lantheus Holdings (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, reported financial results for its second quarter ended June 30, 2022. Lantheus reported Q2 adjusted EPS of 89c versus the consensus estimate of 70c. The company reported Q2 revenue of $223.723M versus the consensus estimate of $204.51M.

Lantheus sees Q3 adjusted EPS of 80c-85c versus the consensus estimate of 69c. The company forecasts Q3 revenue of $220M-$230M versus the consensus estimate of $204.57M.

“Our record-setting financial results for the first half of 2022 reflect the strength of our strategy and our ability to drive long-term growth,” said Mary Anne Heino, President, and CEO. “PYLARIFY, which is firmly established as the PSMA PET imaging agent of choice, continues to propel our growth and have a positive impact on the U.S. prostate cancer community. We continue to be driven by our purpose to Find, Fight and Follow disease to improve patient outcomes and provide sustainable value for shareholders.”

Blackrock and Vanguard Largest Shareholders, Excellent Sales Growth

The largest shareholders in $LNTH stock are Blackrock and Vanguard.

LNTH quarterly sales growth shows excellent growth.
Sales Growth 5 Quarters

The company has shown tremendous sales growth over the last five quarters.

When comparing the Revenue growth rate of the last five years to the growth rate of the upcoming five years, we see that the growth is accelerating.

Revenue has grown by 58.72% in the past year. This is robust growth! Revenue is expected to grow by 25.06% over the next five years.

📺 Lantheus Holdings Stock – Is this Healthcare Stock a Buy ? | LNTH Stock

$LNTH Chart Technical Analysis

$LNTH stock is in a solid technical uptrend. The stock trades within an uptrend channel that began at the end of March 2022. With the rest of the market selling off, that’s excellent relative strength performance! The short-term trend is bullish, and the long-term indicators fully support a continuation of the trend.

Get Email Alerts and Follow Us: